Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which constitutively activates the tropomyosin‐related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity i...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer Vol. 65; no. 10; pp. e27271 - n/a
Main Authors: Halalsheh, Hadeel, McCarville, Mary Beth, Neel, Michael, Reynolds, Mark, Cox, Michael C., Pappo, Alberto S.
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01.10.2018
Subjects:
bone metastasis
Bone remodeling
ETV6–NTRK
Hematology
Infants
larotrectinib
mesoplastic nephroma
Metastases
Neonates
Oncology
Pediatrics
Signal transduction
TRK inhibitor
Tropomyosin
mesoplastic nephroma
larotrectinib
bone metastasis
ETV6-NTRK
TRK inhibitor
ISSN:1545-5009, 1545-5017, 1545-5017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which constitutively activates the tropomyosin‐related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
Bibliography:Funding information
Grant sponsor: Loxo Oncology, Inc.; Grant sponsor: Bayer AG; Grant sponsor: American Lebanese Syrian Associated Charities (ALSAC).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1545-5009
1545-5017
1545-5017
DOI:10.1002/pbc.27271